KRRO vs. MIRM, LGND, HRMY, ZLAB, KNSA, KROS, GLPG, GPCR, INDV, and VRNA
Should you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND), Harmony Biosciences (HRMY), Zai Lab (ZLAB), Kiniksa Pharmaceuticals (KNSA), Keros Therapeutics (KROS), Galapagos (GLPG), Structure Therapeutics (GPCR), Indivior (INDV), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical preparations" industry.
Mirum Pharmaceuticals (NASDAQ:MIRM) and Korro Bio (NASDAQ:KRRO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking.
Korro Bio has a net margin of 0.00% compared to Korro Bio's net margin of -69.67%. Korro Bio's return on equity of -56.46% beat Mirum Pharmaceuticals' return on equity.
Korro Bio has lower revenue, but higher earnings than Mirum Pharmaceuticals.
Mirum Pharmaceuticals currently has a consensus price target of $53.64, suggesting a potential upside of 23.79%. Korro Bio has a consensus price target of $122.50, suggesting a potential upside of 133.42%. Given Mirum Pharmaceuticals' higher probable upside, analysts clearly believe Korro Bio is more favorable than Mirum Pharmaceuticals.
13.2% of Korro Bio shares are owned by institutional investors. 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 16.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Mirum Pharmaceuticals received 110 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 74.39% of users gave Mirum Pharmaceuticals an outperform vote.
In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Korro Bio. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 2 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.61 beat Mirum Pharmaceuticals' score of 0.30 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.
Mirum Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500.
Summary
Mirum Pharmaceuticals beats Korro Bio on 10 of the 17 factors compared between the two stocks.
Get Korro Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Korro Bio Competitors List
Related Companies and Tools
